Skip to Main Content

Paper Details

A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy.
Breast
1
2023
Author NameAffiliation
Alberto ZambelliHumanitas University, Humanitas Cancer Center, IRCCS Humanitas Research Hospital
  • 1 - 1

Datasets

Release 1.2